FDA granted Fast Track designation to immuno-oncology products Toca 511 and Toca FC, developed by Tocagen Inc., for the treatment of recurrent high grade glioma, including glioblastoma and anaplastic astrocytoma. A study in this indication is planned for later this year, according to Tocagen.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
